Jianping Xiong
Nanchang University(CN)First Affiliated Hospital of Jiangxi Medical College(CN)Jiangxi Provincial Cancer Hospital(CN)First Affiliated Hospital of Nanchang University(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cancer-related molecular mechanisms research, Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction(2016)985 cited
- → Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial(2009)774 cited
- → Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial(2020)632 cited
- → Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study(2023)612 cited
- → Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study(2020)575 cited